Sympathetic use of latanoprost 0.005% in 30 eyes.
In this study, the authors report their experience with latanoprost after a year's treatment of patients with various forms of glaucoma at various stages of progression. The new drug was associated also with different beta-blockers. The case file reported includes 30 eyes of 18 patients treated with latanoprost once a day in the evening. Follow-up varied from 6 months to 1 year. Except for 2 patients (3 eyes) receiving only latanoprost therapy, all the others received latanoprost in association with their on-going therapy. Results are equivalent to those described in the literature. The authors also consider the results in two groups; chronic simple glaucoma and other forms of glaucoma. From their own experience and from what is reported in the literature, the authors conclude by stressing the pressure reducing efficacy of this drug.
Montrone
F
F
Oculistics Division, Di Venere Hospital, Bari.
Macinagrossa
G
G
Tenerelli
F
F
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D010277:Parasympathomimetics / Q000008:administration & dosage / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D013564:Sympathetic Nervous System / Q000187:drug effects*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects